Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPC for Prevention of Sarcopenia
NCT02575235Phase 1Completed
- Sponsor
- Seoul National University Hospital
- Start
- Oct 2015
- Primary completion
- Jul 2016
- Modality
- Conventional Liposomes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cetylpyridinium chloride in Sarcopenia (3 arms), sponsored by Seoul National University Hospital. Primary endpoint: Procollagen type III N-terminal peptide at 8 weeks. Started Oct 2015; status: completed.
02
Drugs
cetylpyridinium chloride
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT02575235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575235.